Clinical Trial

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

Study acronym: APPART
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study seeks to validate the hypothesis that nulliparous pregnant women after Assisted Reproductive Technology (ART) are at high risk of preeclampsia and perinatal complications and represent a subgroup for which aspirin prophylaxis during pregnancy may be effective in the prevention of preterm preeclampsia and other perinatal adverse outcomes.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-11-22; most recent amendment 2026-05-04.
Status change: Not Yet Recruiting → Recruiting 2023-12-08
Trial Details
NCT Number NCT05625724
Lead Sponsor University Hospital, Toulouse
Conditions ART, Pre-Eclampsia
Enrollment 1,164 participants
Start Date 2023-08-02
Primary Completion 2028-08 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-07